Yahoo
NYSEArca - Delayed Quote USD

State Street Health Care Select Sector SPDR ETF (XLV)

145.99 +3.15 (+2.21%)
At close: April 30 at 4:00:00 PM EDT
146.30 +0.39 (+0.27%)
Pre-Market: 8:51:06 AM EDT
Trade XLV on Coinbase
Chart Range Bar
Loading chart for XLV
  • Previous Close 142.84
  • Open 143.68
  • Bid 145.28 x 70000
  • Ask --
  • Day's Range 143.69 - 146.29
  • 52 Week Range 127.35 - 160.59
  • Volume 11,623,963
  • Avg. Volume 13,402,075
  • Net Assets 38.6B
  • NAV 145.94
  • PE Ratio (TTM) 25.72
  • Yield 1.71%
  • YTD Daily Total Return -5.30%
  • Beta (5Y Monthly) 0.71
  • Expense Ratio (net) 0.08%

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

State Street Investment Management

Fund Family

Health

Fund Category

38.6B

Net Assets

1998-12-16

Inception Date

Performance Overview: XLV

View More

Trailing returns as of 4/30/2026. Category is Health.

YTD Return

XLV
5.30%
Category
3.99%

1-Year Return

XLV
5.78%
Category
18.75%

3-Year Return

XLV
4.74%
Category
7.01%

People Also Watch

Holdings: XLV

View More

Top 10 Holdings (59.01% of Total Assets)

Symbol Company % Assets
LLY 13.72%
JNJ 11.09%
ABBV 7.23%
MRK 5.62%
UNH 4.61%
AMGN 3.57%
TMO 3.48%
ABT 3.36%
GILD 3.25%
ISRG 3.08%

Sector Weightings

Research Reports: XLV

View More
  • Biogen Earnings: Strong First Quarter, Eventful Year Ahead

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • Biogen Earnings: Eventful Year Ahead Despite Expected Decline in Revenue

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • AI driving growth, raising target price to $450

    Taiwan Semiconductor Manufacturing Company Ltd., headquartered in Hsinchu, Taiwan, was founded in 1987 and pioneered the pure-play foundry or 'merchant fab' model. The company serves both integrated semiconductor producers who outsource a portion of their production as well as 'fabless' semiconductor producers who outsource all manufacturing. Taiwan Semi serves over 500 semiconductor customers, producing more than 11,500 distinct products while providing a broad range of advanced, specialty, and advanced packaging technologies.

    Rating
    Price Target
  • ASML Earnings: Outlook Is Magnificent, but Valuation Overshoots Our Fair Value Estimate

    ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: